Phospholipid transfer protein in hemodialysis patients

American Journal of Nephrology

Volumn 27, Issue 2, 2007, Pages 138-143

  Schlitt, Axel ^a,c   Heine, Gunnar H ^b   Jiang, Xian Cheng ^d   Messow, Martina ^c   Blankenberg, Stefan ^c   Rupprecht, Hans J ^c   Ulrich, Christof ^b   Buerke, Michael ^a   Werdan, Karl ^a   Lackner, Karl J ^c   Köhler, Hans ^b   Girndt, Matthias ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Atherosclerosis; High density lipoprotein metabolism; Phospholipid transfer protein; Uremic dyslipidemia

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; RISK ASSESSMENT; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DYSLIPIDEMIAS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; PROGNOSIS; RENAL DIALYSIS;

EID: 34247158604     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099943     Document Type: Article

References (29)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112-S119.
2. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
3. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group: K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;4:S1-S91.
4. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:573-592.
5. Uhlig K, Levey AS, Sarnak MJ: Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial 2003;16:118-127.
6. Tall AR, Jiang X, Luo Y, Silver D: 1999 George Lyman Duff Memorial Lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:1185-1188.
7. Barter PJ, Rye KA: Cholesteryl ester transfer protein, high-density lipoprotein and arterial disease. Curr Opin Lipidol 2001;12:377-382.
8. Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ: Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low-density lipoproteins and high-density lipoproteins during lipolysis. J Lipid Res 1985;26:842-851.
9. Jiang XC, Qin S, Qiao C, Kawano K, Lin M, Skold A, Xiao X, Tall AR: Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001;7:847-852.
10. Jiang XC, Tall AR, Qin S, Lin M, Schneider M, Lalanne F, Deckert V, Desrumaux C, Athias A, Witztum JL, Lagrost L: Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem 2002;277:31850-31856.
11. Van Haperen R, van Tol A, van Gent T, Scheek L, Visser P, van der Kamp A, Grosveld F, de Crom R: Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 2002;277:48938-48943.
12. Yang XP, Yan D, Qiao C, Liu RJ, Chen JG, Li J, Schneider M, Lagrost L, Xiao X, Jiang XC: Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 2003;23:1601-1607.
13. Yan D, Navab M, Bruce C, Fogelman AM, Jiang XC: PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res 2004;45:1852-1858.
14. Schlitt A, Liu J, Yan D, Mondragon-Escorpizo M, Norin AJ, Jiang XC: Anti-inflammatory effects of phospholipid transfer protein deficiency in mice. Biochim Biophys Acta 2005;1733:187-191.
15. Schlitt A, Bickel C, Thumma P, Blankenberg S, Rupprecht HJ, Meyer J, Jiang XC: High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:1857-1862.
16. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-482.
17. Iseki K, Yamazato M, Tozawa M, Takishita S: Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;61:1887-1893.
18. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.
19. Cheung MC, Brown BG, Marino Larsen EK, Frutkin AD, O'Brien KD, Albers JJ: Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Biochim Biophys Acta 2005;1762:131-137.
20. Pussinen PJ, Metso J, Malle E, Barlage S, Palosuo T, Sattler W, Schmitz G, Jauhiainen M: The role of plasma phospholipid transfer protein in HDL remodeling in acute-phase patients. Biochim Biophys Acta 2001;1533:153-163.
21. Barlage S, Frohlich D, Bottcher A, Jauhiainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G: ApoE-containing high-density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 2001;42:281-290.
22. Murdoch SJ, Carr MC, Hokanson JE, Brunzell JD, Albers JJ: PLTP activity in premenopausal women: relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J Lipid Res 2000;41:237-244.
23. Cheung MC, Wolfbauer G, Kennedy H, Brown BG, Albers JJ: Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin. Biochim Biophys Acta 2001;1537:117-124.
24. Huuskonen J, Ekstrom M, Tahvanainen E, Vainio A, Metso J, Pussinen P, Ehnholm C, Olkkonen VM, Jauhiainen M: Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis 2000;151:451-461.
25. Van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, Ehnholm S, Grosveld F, van der Kamp A, de Crom R: Human plasma phospholipid transfer protein increases the antiatherogenic potential of high-density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000;20:1082-1088.
26. Cheung MC, Brown BG, Marino Larsen EK, Frutkin AD, O'Brien KD, Albers JJ: Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Biochim Biophys Acta 2006;1762:131-137.
27. Jurek A, Turyna B, Kubit P, Klein A: LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure. Clin Biochem 2006;39:19-27.
28. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castelani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-287.
29. Dirican M, Akca R, Sarandol E, Dilek K: Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 2004;17:813-818.